Multi-clinic Action Trial to Control Hyperglycemia and Hypertension

Overview

The MATCH2 Study (The Multi-clinic Action Trial to Control Hyperglycemia and Hypertension) is a randomized controlled trial comparing two educational approaches to improve glucose and blood pressure control in African American and Latino adults with type 2 diabetes. The study is being designed and implemented using a Community Based Participatory Research approach to optimize the two educational approaches. One approach, Enhanced Home Based Education, adapts a Community Health Worker (CHW) intervention from the protocol of the prior Mexican-American Trial of Community Health workers (MATCH). The other approach, Enhanced Clinic Based Education, uses a Certified Diabetes Educator (CDE) to deliver dietary and general self-management education. The study seeks to determine if Community Health Workers working as part of the primary care clinical team can reduce health disparities and improve outcomes among patients with type 2 diabetes.

Full Title of Study: “MATCH2: The Multi-clinic Action Trial to Control Hyperglycemia and Hypertension”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Double (Investigator, Outcomes Assessor)
  • Study Primary Completion Date: December 2018

Detailed Description

MATCH2, a randomized controlled trial, will test if the optimized CHW-delivered intervention can reduce both Hemoglobin A1c levels and blood pressure at eighteen months in persons with uncontrolled diabetes, as compared to a CDE-delivered group educational program. Follow-up six months after the completion of the intervention will evaluate the sustainability of any gains. MATCH2 will use precise measures of diet (food frequency questionnaires) and physical activity (accelerometry) to identify intermediate behaviors and processes that mediate significant improvements in glycemic and blood pressure control.

Patients/participants will be recruited from three participating urban primary care safety net clinics to join MATCH2 if patients meet the inclusion and exclusion conditions (see criteria section below). Eligible patients interested in participation will have a baseline visit scheduled. Baseline assessments may be conducted either at the clinic, the participant's home, or the Rush Prevention Center, at the patient's preference. At the baseline visit, the research assistant will obtain informed consent for the study as approved by the Institutional Review Boards (IRB) of participating institutions. The baseline assessment will include the following measures: demographics, clinical data, glycemic control, blood pressure, total caloric and sodium intake, physical activity, medication adherence, clinic attendance, quality of life, patient activation, depression and social support.

A randomization scheme based on permuted randomized blocks of size 4 and 6 will be used, stratified by clinic. Randomization schedules will be developed by the study Biostatistician and the Data Management Team will assign participants to treatment or control groups accordingly.Of the investigative team, the Principal Investigator, identified Key Co-Investigators and all research assistants will be blinded to the patient's group assignment while remaining research team: the Community Health Workers (blinded to study hypothesis), selected Key Co-Investigators, Site Principal Investigators, and Data Management Team will be unblinded.

Participants will know the study condition to which participants have been assigned. As with the CHW interventionists, participants will be blinded to the study hypothesis. Consent and recruitment forms will all state that "The MATCH2 trial is comparing two clinic-based approaches to improve control of high blood sugar and high blood pressure in people with type 2 diabetes. Some evidence suggests that approaches such as health classes led by a diabetes educator, coaching by Community Health Workers, and printed diabetes education materials may help improve outcomes for people with uncontrolled diabetes.

ENHANCED HOME-BASED EDUCATION CONDITION: CHW Interventionists deliver diabetes self-management curriculum in the participant's home or other preferred setting.

MATCH2 Trained CHW Interventionists will work closely with patients to deliver a participant-centered intervention derived from two pragmatic evidence-based frameworks for behavioral change [Motivational Interviewing (MI) and Kate Lorig's Chronic Disease Self-Management approach]. 24 total in-person visits will be conducted; six primary topics will be covered multiple times over an 18-month period. No more than two topics will be addressed at any visit. The sequence in which topics are delivered is determined by participant need, preference, and interest. The six primary topics are:

1. Check glucose daily and know the goal.

2. Check blood pressure daily and know the goal.

3. Understand medications and take medications as prescribed.

4. Engage in 30 minutes of physical activity every day.

5. Enjoy a healthy natural diet with vegetables, fruit, and fiber.

6. Communicate any concerns to the health care team.

At each visit, CHWs will help participants develop a self-management Action Plan around one of the six topics, and support problem solving behaviors to address barriers to completing the Action Plan. Behavioral self-management skills will be taught by the CHW and practiced with the participant at each visit. CHWs will monitor the clinic attendance of participants and will advise and assist participants with making appointments with their primary care providers at least once every 4 months. CHWs will also play an active role in communicating the progress of their participants to the primary care providers using the clinic Electronic Medical Record.

ENHANCED CLINIC-BASED EDUCATION CONDITION: Participants will receive group diabetes self-management education, consistent with current Medicare guidelines for diabetes education. A Certified Diabetes Educator will deliver the two class sessions (each two hours) covering basic topics: diabetes (including self-management) and nutrition. Participants will also receive 24 bilingual educational newsletters: twelve during the first six months and then once a month between 6 and 18 months. The newsletters, called "Diabetes Action", cover the same six self-management topics listed previously.

Interventions

  • Behavioral: Home Based Enhanced Education
    • The Home Based Enhanced Education arm consists of a diabetes self-management curriculum delivered by Community Health Workers in the participant’s home. Participants receive 24 visits: 12 biweekly visits in the first 6 months, followed by 12 monthly visits in months 6 through 18 of the study. The self-management program is derived from two pragmatic evidence-based frameworks for behavioral change.
  • Behavioral: Clinic Based Enhanced Education
    • The Clinic Based Enhanced Education arm consists of two two-hour-long sessions of group diabetes self-management education, delivered by a Certified Diabetes Educator. Participants in this arm will also receive 24 newsletters with diabetes self-management education.

Arms, Groups and Cohorts

  • Experimental: Home Based Enhanced Education
    • The Home Based Enhanced Education arm consists of a diabetes self-management curriculum delivered by Community Health Workers in the participant’s home.
  • Active Comparator: Clinic Based Enhanced Education
    • The Clinic Based Enhanced Education arm consists of group diabetes self-management education, delivered by a Certified Diabetes Educator, plus mailed diabetes self-management education.

Clinical Trial Outcome Measures

Primary Measures

  • Glycemic Control
    • Time Frame: Up to 18 months post randomization
    • Glycemic control will be determined by Hemoglobin A1c, measured on a fingerstick collected Dried Blood Spot test, and analyzed by an independent reference lab.
  • Blood Pressure Control
    • Time Frame: Up to 18 months post randomization
    • Blood Pressure (BP) will be measured three times using an automated blood pressure cuff with the participant in a seated position. Mean Arterial Pressure will be calculated by the standard formula: Diastolic BP + 1/3 (Systolic BP – Diastolic BP)] .

Secondary Measures

  • Maintenance of Glycemic Control
    • Time Frame: Up to 24 months post randomization
    • Glycemic control will be determined by Hemoglobin A1c, measured on a fingerstick collected Dried Blood Spot test, and analyzed by an independent reference lab.
  • Maintenance of Blood Pressure Control
    • Time Frame: Up to 24 months post randomization
    • Blood Pressure (BP) will be measured three times using an automated blood pressure cuff with the participant in a seated position. Mean Arterial Pressure will be calculated by the standard formula: Diastolic BP + 1/3 (Systolic BP – Diastolic BP)] .
  • Intermediate Behavior: Dietary Adherence
    • Time Frame: Up to 18 months
    • Repeated 24-hour dietary recalls using the Nutrition Data System for Research (NDSR)
  • Intermediate Behavior: Physical Activity
    • Time Frame: Up to 18 months
    • Accelerometer, worn for one week.
  • Intermediate Behavior: Medication Adherence
    • Time Frame: Up to 18 months
    • Morisky 8-item questionnaire (MMAS-8)

Participating in This Clinical Trial

Inclusion Criteria

  • Diagnosis of type 2 diabetes mellitus with A1c greater than or equal to 7.0
  • At least 18 years of age and capable of giving informed consent in either English or Spanish
  • Primary care received through a participating clinic
  • Participants must identify themselves as either Black / African American race or Hispanic / Latino ethnicity

Exclusion Criteria

  • Have end-stage renal disease, stroke, or other major end-organ complication of diabetes
  • Require chronic prednisone or other systemic corticosteroid use
  • Are receiving treatment for a major psychiatric disorder (i.e. schizophrenia)
  • Live in a household with someone who is already a randomized study participant

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Rush University Medical Center
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Steven K Rothschild, MD, Principal Investigator, Rush University Medical Center
  • Overall Contact(s)
    • Steven K Rothschild, MD, 312-942-3476, Steven_K_Rothschild@rush.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.